LEADER 03979nam 22006855 450 001 9910298626103321 005 20200630072025.0 010 $a3-319-11502-2 024 7 $a10.1007/978-3-319-11502-3 035 $a(CKB)3710000000261988 035 $a(EBL)1968133 035 $a(OCoLC)908088801 035 $a(SSID)ssj0001372337 035 $a(PQKBManifestationID)11785439 035 $a(PQKBTitleCode)TC0001372337 035 $a(PQKBWorkID)11302004 035 $a(PQKB)11448494 035 $a(DE-He213)978-3-319-11502-3 035 $a(MiAaPQ)EBC1968133 035 $a(PPN)182099423 035 $a(EXLCZ)993710000000261988 100 $a20141013d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aSmall Molecule Therapeutics for Schizophrenia /$fedited by Sylvain Celanire, Sonia Poli 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (327 p.) 225 1 $aTopics in Medicinal Chemistry,$x1862-2461 ;$v13 300 $aDescription based upon print version of record. 311 $a3-319-11501-4 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aAntipsychotics and the Dopamine?Serotonin Connection -- GLYT1 Inhibitors: From Hits to Clinical Candidates -- Metabotropic Glutamate Receptor 2 Activators -- Activation of the mGlu5 Receptor for the Treatment of Schizophrenia and Cognitive-Deficit-Associated Disorders -- Muscarinic Acetylcholine Receptor Activators -- Nicotinic Acetylcholine Receptor Modulators -- The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia. 330 $aThe topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drug ability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. 410 0$aTopics in Medicinal Chemistry,$x1862-2461 ;$v13 606 $aMedicinal chemistry 606 $aPsychopharmacology 606 $aNeurosciences 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 615 0$aMedicinal chemistry. 615 0$aPsychopharmacology. 615 0$aNeurosciences. 615 14$aMedicinal Chemistry. 615 24$aPsychopharmacology. 615 24$aNeurosciences. 676 $a616.8982 702 $aCelanire$b Sylvain$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aPoli$b Sonia$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298626103321 996 $aSmall Molecule Therapeutics for Schizophrenia$91939241 997 $aUNINA